Anemos Bio is part of the inaugural AI Lift for researchers cohort. Nebius says each team receives Nebius compute, hands-on support from solutions architects, business workshops and investor introductions during the eight-week pilot.
The company creates lung cancer cell lines from current patients through U.S. clinical partnerships, pairing them with genomic, proteomic, drug-response and clinical data. It aims to build around 1,000 cell lines and eight million cell line–drug pairs. Its research approach validates AI predictions in the same cells used to train its models.
Nebius names Anemos Bio among its inaugural AI Lift research teams and states that each team receives Nebius compute and engineering support during an eight-week pilot. The article describes Anemos Bio’s patient-derived lung cancer cell models, paired biological data and research targets.
The Lab Gets a Lift12 Oct 2026 · Nebius Science · Web pageNebius names Anemos Bio among its inaugural AI Lift research teams and states that each team receives Nebius compute and engineering support during an eight-week pilot. The article describes Anemos Bio’s patient-derived lung cancer cell models, paired biological data and research targets.
Nebius Science AI Lift cohort announcement
18 Oct 2026 · LinkedIn · Web page
Nebius Science identifies Anemos Bio as a team joining its eight-week AI Lift pilot with access to GPU compute, engineering support and business guidance.
Nebius Science AI Lift cohort announcement18 Oct 2026 · LinkedIn · Web pageNebius Science identifies Anemos Bio as a team joining its eight-week AI Lift pilot with access to GPU compute, engineering support and business guidance.
Anemos Bio develops patient-derived cancer cell models and paired biological data for researchers and cancer drug developers, initially focusing on lung cancer. Its Anemos Atlas is a collection of living cells grown from patient tumors, including cancers previously treated or resistant to therapy. The company pairs these models with genomic, transcriptomic, proteomic and drug-response data. It is also developing AI models to predict treatment responses, identify drug targets and improve drug candidates, with predictions tested against the living cell collection.
Documented financing · private company
AmountUndisclosedIn-kind compute grant — Nebius AI Lift for researchers
Anemos Bio builds patient-derived cancer cell models and paired biological data to support cancer drug development. · Health
How they use Nebius AI Cloud
Anemos Bio is part of the inaugural AI Lift for researchers cohort. Nebius says each team receives Nebius compute, hands-on support from solutions architects, business workshops and investor introductions during the eight-week pilot.
The company creates lung cancer cell lines from current patients through U.S. clinical partnerships, pairing them with genomic, proteomic, drug-response and clinical data. It aims to build around 1,000 cell lines and eight million cell line–drug pairs. Its research approach validates AI predictions in the same cells used to train its models.
Nebius names Anemos Bio among its inaugural AI Lift research teams and states that each team receives Nebius compute and engineering support during an eight-week pilot. The article describes Anemos Bio’s patient-derived lung cancer cell models, paired biological data and research targets.
The Lab Gets a Lift12 Oct 2026 · Nebius Science · Web pageNebius names Anemos Bio among its inaugural AI Lift research teams and states that each team receives Nebius compute and engineering support during an eight-week pilot. The article describes Anemos Bio’s patient-derived lung cancer cell models, paired biological data and research targets.
Nebius Science AI Lift cohort announcement
18 Oct 2026 · LinkedIn · Web page
Nebius Science identifies Anemos Bio as a team joining its eight-week AI Lift pilot with access to GPU compute, engineering support and business guidance.
Nebius Science AI Lift cohort announcement18 Oct 2026 · LinkedIn · Web pageNebius Science identifies Anemos Bio as a team joining its eight-week AI Lift pilot with access to GPU compute, engineering support and business guidance.
Anemos Bio develops patient-derived cancer cell models and paired biological data for researchers and cancer drug developers, initially focusing on lung cancer. Its Anemos Atlas is a collection of living cells grown from patient tumors, including cancers previously treated or resistant to therapy. The company pairs these models with genomic, transcriptomic, proteomic and drug-response data. It is also developing AI models to predict treatment responses, identify drug targets and improve drug candidates, with predictions tested against the living cell collection.
Documented financing · private company
AmountUndisclosedIn-kind compute grant — Nebius AI Lift for researchers
